Articles les plus consultés
-
francis 13 Version sans publicité Marchés Actualités Analyses Crypto Fonds Graphiques Technique Brokers Outils Portefe...
-
6% Hydroxyethyl Starch 130 / 0.4 in 0.9% Injection de chlorure de sodium (Voluven 500 mL freeflex flexible en plastique intraveineuse solut...
-
Top Gaining Stocks % Chg Dernier Symb Compagnie Le volume 16,22% 2.15 SRNE Sorrento Therapeut 7030 10,92% 2,64 CIE Cobalt Inte...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Iridium 14.95 + 39.07% 0,60K Mondialisation de l'Inde. 0,4800 + 18,52% 1,80K...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Oracle Corporation 51.30 + 10,73% 58.90K Staples Inc 9.25 + 6,81% 12,31K Delcat...
-
Citoyens_Français @citoyenneFrance 8 juin Plus Attali : « Les élus n’ont plus de pouvoir et voici votre avenir » - Effr......
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Lipocine In 5.32 + 32,34% 38.64K Enphase Energy Inc 0,938 + 17,57% 10,37K Delca...
-
Pre Market Top Gainers prénom Dernier Chg. % Vol. Delcath 0.1230 + 24,24% 196,67K Neos Therapeutics I. 10.50 +16.67% 34.36K Enpha...
-
28 juin 2017 Nom du médicament et numéro de demande Ingrédient actif Formulaire de posologie / itinéraire Soumission Compagnie ...
-
Plus fortes hausses en préouverture Nom Dernier Var.% Vol. DragonWave Inc 1,3900 +25,23% 3,55K Alibaba 139,95 +11,35% 1,40M MoSys...
jeudi 17 mai 2018
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma | Business Wire
Exelixis’ Partner Ipsen Announces European Commission Approval of CABOMETYX® (Cabozantinib) for Previously Untreated Intermediate- or Poor-Risk Advanced Renal Cell Carcinoma | Business Wire: Exelixis, Inc. (Nasdaq:EXEL) today announced that its partner Ipsen received approval from the European Commission (EC) for CABOMETYX® (cabozantinib)
AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing | Business Wire
AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing | Business Wire: AHF: Congenital Syphilis Rates a ‘Tragedy’ and L.A. County Does Nothing
Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC | Business Wire
Viz.ai to Present Expanded Data on ALADIN and New Data on ADVANCE Expanding Its Stroke Pipeline at the 2018 ESOC | Business Wire: Viz.ai, an applied artificial intelligence healthcare co, to present expanded ALADIN and new ADVANCE data expanding its stroke pipeline at ESOC 2018
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions | Business Wire
Celgene to Present New Clinical Data in Blood Cancer and Solid Tumor Therapies at Upcoming American Society of Clinical Oncology (ASCO) Scientific Sessions | Business Wire: Celgene to Present New Clinical Data at ASCO 2018 highlighting the value of innovative research in key blood cancer and solid tumor disease areas
Minomic Completes Prospective Clinical Study Using MiCheck® to Assist in Diagnosis of Prostate Cancer | Business Wire
Minomic Completes Prospective Clinical Study Using MiCheck® to Assist in Diagnosis of Prostate Cancer | Business Wire: Minomic International Ltd announced the completion of its Prospective Clinical Trial of the company's novel prostate cancer diagnostic test, MiCheck®.
mercredi 16 mai 2018
Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD | Business Wire
Vitrisa Therapeutics Acquires Rights to MAKO Clinical Trial Data in wAMD | Business Wire: Vitrisa Therapeutics, Inc., a Company focused on developing a suite of platform technologies optimized for ocular therapeutics and an associated pipel
Inscription à :
Commentaires (Atom)